tbuckley/cabot-search huggingface dataset:
Quantification of postural control deficits in patients with recent concussion: an inertial-sensor based approach
Authors: Cailbhe Doherty, Brian Caulfield, John Ryan, Yusuke Komaba, Akihiro Inomata, Liang Zhao
Journal: British Journal of Sports Medicine (2017)

Objective To quantify postural control ability in a group with concussion compared with a ‘healthy’ control group. Design Case-control study. Setting University Biomechanics Laboratory. Participants Fifteen concussion patients (4 females, 11 males) and a group of fifteen age- and sex- matched controls. Participants were excluded if they had any: lower extremity injury that may affect gait; history of cognitive deficiencies; history of ≥3 previous concussions; loss of consciousness following the concussion for &gt;1 minute; a previously documented concussion in the previous year Independent variable Group; Task (3 stance variants of the Balance Error Scoring System [BESS]) Outcome measures Sway area as computed using a force-plate and sway volume as computed from an accelerometer placed on the sacrum during performance of the BESS. Main results Concussed patients exhibited increased sway area (1500 mm 2 [95% CI: 900 to 2000 mm 2 ] vs 650 mm 2 [95% CI: 520 to 780 mm 2 ] p=0.02) and sway volume (9.5 m 3 s –6 [95%CI: 8 to 20 m 3 s –6 ] vs 2.80 m 3 s –6 [95% CI: 1.8 to 3.6 m 3 s –6 ]) in the bilateral stance position of the BESS. The sway volume metric also had excellent accuracy in identifying task ‘errors’ (tandem stance: 95% CI: 80–96%, p&lt;0.001; unilateral stance: 95% CI: 85–95%, p&lt;0.001). Conclusions Individuals with concussion display increased postural sway during bilateral stance. The sway volume that was calculated from the accelerometer data not only differentiated a group with concussion from a healthy control group, but successfully identified when task errors had occurred. This may be of value in the development of a pitch-side assessment system for concussion. Competing interests None.
Intratumor Heterogeneity and Circulating Tumor Cell Clusters
Authors: Zafarali Ahmed, Simon Gravel
Journal: Molecular Biology and Evolution (2017)

Genetic diversity plays a central role in tumor progression, metastasis, and resistance to treatment. Experiments are shedding light on this diversity at ever finer scales, but interpretation is challenging. Using recent progress in numerical models, we simulate macroscopic tumors to investigate the interplay between growth dynamics, microscopic composition, and circulating tumor cell cluster diversity. We find that modest differences in growth parameters can profoundly change microscopic diversity. Simple outwards expansion leads to spatially segregated clones and low diversity, as expected. However, a modest cell turnover can result in an increased number of divisions and mixing among clones resulting in increased microscopic diversity in the tumor core. Using simulations to estimate power to detect such spatial trends, we find that multiregion sequencing data from contemporary studies is marginally powered to detect the predicted effects. Slightly larger samples, improved detection of rare variants, or sequencing of smaller biopsies or circulating tumor cell clusters would allow one to distinguish between leading models of tumor evolution. The genetic composition of circulating tumor cell clusters, which can be obtained from non-invasive blood draws, is therefore informative about tumor evolution and its metastatic potential.
AB0895 Are lateral spine bone mineral density measurements useful in axial spondyloarthritis?
Authors: W. Hamdi, D. Ben Nessib, H. Riahi, A. Kasraoui, K. Maatallah, M.D. Kaffel, M. Bouaziz, M.F. Ladeb, M.M. Kchir
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Bone loss leading to osteoporosis (OP) is a well-known feature of axial spondyloarthritis (AS) although this disease is characterised by calcification in extra osseous tissues and new bone formation. In fact, dual-energy X-ray absorptiometry (DEXA) is the most common imaging method used to measure the bone mineral density (BMD). However, many studies have shown an inferiority of the postero-anterior (PA) spine measurements in reflecting the bone loss compared to lateral spine measurements because of the bridging syndesmophytes which may overestimate the BMD. <h3>Objectives</h3> Our aim is to evaluate the Lateral spine BMD (L-BMD) in AS and to assess its association with the disease features. <h3>Methods</h3> Seventy-five patients who met the Modified New York Classification criteria for AS were enrolled in this cross-sectional study. BMD was measured using DEXA at PA lumbar, lateral lumbar and hip regions. <h3>Results</h3> Sixty-two men and 13 women were enrolled with an average age of 36.8±11.8 years. Bone loss (osteopenia or OP) was noted in 65% of the patients (n=46) in PA lumbar and in 63% in lateral lumber (n=45). In L-BMD, BMD was correlated with early menopause and vitamin D level (p=0.01 and p=0.04 respectively). T-score in lateral spine was correlated with coffee consumption (p=0.02), physical inactivity (p=0.037), sexual hormones disorders (p=0.02), hip arthritis (p=0.017), BASMI (p=0.001), BASFI (p=0.03) and ASDAS<sub>VS</sub> (p=0.03) scores, ESR (p=0.003) and CRP (p=0.03) levels, and hip (p=0.004), spine (p=0.007) and total (p=0.001) BASRI. <h3>Conclusions</h3> L-BMD seems to be a reliable measurement in AS, and may avoid the overestimation of the BMD values and allows consequently to detect spinal osteoporosis and prevent fractures in AS. <h3>References</h3> [1] El Maghraou A, Borderie D, Cherruau B, Edouard R, Roux C, Dougados M (1999) Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol26:2205–2209 [2] Mitra D, Elvins DM, Speden DJ, Collins AJ (2000) The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology39:85–89 <h3>Disclosure of Interest</h3> None declared
PARE0003 Providing patient and family education and support for children with rheumatic diseases and their families: cassie and friends annual family day in bc
Authors: J. Wilson, L. Tucker
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Family Day, an annual patient education event starting in 2009, is organized and funded by Cassie and Friends, a registered BC charity dedicated to transforming the lives of children with rheumatic diseases and their families. It is a full day, multi-track conference held outside the hospital environment, organized collaboratively by the pediatric rheumatology team members at BC Children’s Hospital and the Cassie and Friends’ volunteer conference committee. <h3>Objectives</h3> To describe the growth and impact of an annual Family Day event on children with rheumatic diseases and their families in BC. <h3>Methods</h3> The program includes lectures, round table discussions, and patient panels for parents and caregivers, with both age-related recreational and educational activities for children and youth (i.e. peer to peer support). Content and format of the program is informed annually by feedback from previous Family Days and advice from pediatric rheumatology team members. Formal feedback from attendees (parents) is provided by a post-event survey. <h3>Results</h3> Registration has increased annually from just a hadnful of families in 2009 to 141 attendees in 2015, and 372 attendees in 2017( with a waitlist). In 2017, attendees were 81 children and youth with rheumatic diseases, 68 siblings, and 150 parents and caregivers. A total of 72 speakers and volunteers participated. 186 participants had attended Family Day the previous year; 148 participants were first time attendees. Families came from 29 communities throughout British Columbia. 59% of attendees completed the post-event survey. The event was rated as very good or excellent by 98% of respondents, with most stating they would recommend Family Day to other families, and planned to attend the event next year. Parents enjoyed opportunities to meet other parents and health professionals in small interactive groups, and asked for more actionable strategies to help them with their children. The post-meeting questionnaire identified what families perceived as their greatest challenges in dealing with their child’s rheumatic disease: day-to-day family life, pain, well-being, school, medications and treatments, and fear. Please also see our Family Day video with kids and teens sharing what the day means to them: https://vimeo.com/234426339 <h3>Conclusions</h3> A family-centered interactive educational and recreational day offers the opportunity for peer-to-peer connections, education and support for families of children, and youth with rheumatic diseases, and promotes the formation of a strong community addressing family and child needs. <h3>Disclosure of Interest</h3> None declared
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
Authors: Hiroji Iwata, Kenji Tamura, Toshihiko Doi, Junji Tsurutani, Shanu Modi, Haeseong Park, Ian E. Krop, Yasuaki Sagara, Charles H. Redfern, Rashmi Krishna Murthy, Rebecca A. Redman, Kohei Shitara, Yoshihiko Fujisaki, Masahiro Sugihara, Lin Zhang, Javad Shahidi, Antoine Yver, Shunji Takahashi
Journal: Journal of Clinical Oncology (2018)

2501 Background: DS-8201a is a HER2-targeted antibody drug conjugate with novel topoisomerase I inhibitor payload and linker technology. Methods: This ongoing phase 1 study (NCT02564900) enrolls subjects (sbj) with HER2+ breast cancer (BC) post T-DM1, HER2+ gastric cancer (GC) post trastuzumab, HER2 low BC (IHC 1+ or 2+, ISH-), and other HER2-expressing solid tumors (IHC ≥1+). Results: [Results will be updated for presentation at meeting] From Sep 2015–Dec 2017, 212 sbj received ≥1 dose of DS-8201a; 200 at 5.4 or 6.4 mg/kg. Median (mdn) age was 59 y with mdn of 4 prior regimens. At data cutoff, 121/200 (60.5%) sbj remain on treatment (tx). Mdn duration of tx was 10.3 mo (range 0.7+, 21.2+ mo). Overall, RECIST-confirmed overall response rate (ORR) in the evaluable sbj was 81/160 (50.6%) with the highest ORR in HER2+ BC (64.2%). Mdn duration of response was not reached (NR, range 0.03+, 15.2+ mo). 155/181 (85.6%) of sbj with ≥1 postbaseline scan (ps) experienced tumor shrinkage (92.3% of them at 1st ps at 6 weeks). Major reasons for tx discontinuation were progressive disease (PD; 50/200; 25.0%) and adverse event (AE; 18/200; 9.0%); 93/200 (46.5%) experienced a grade ≥3 AE. Common AEs included nausea 73.5% (3.5% grade ≥3), decreased appetite 59.5% (4.5% grade ≥3) and vomiting 39.5% (1.5% grade ≥3). Two grade 5 cases of interstitial lung disease were reported. Conclusions: DS-8201a shows antitumor activity in multiple tumor types with high ORR and durable responses in heavily pretreated sbj. Clinical trial information: NCT02564900. Confirmed ORR (95% CI)* DCR (95% CI) DOR, Mdn (95% CI), mo Duration of FU, Mdn Min, Max, mo PFS, Mdn (95% CI), mo OS, Mdn (95% CI), mo HER2+ BC 43/67, 64.2% (51.5, 75.5) 63/67, 94.0% (85.4, 98.3) 7.6 (NA) 6.0 0.7, 21.2 10.4 (NA) NR HER2+ GC 19/43, 44.2% (29.1, 60.1) 34/43, 79.1% (64.0, 90.0) 7.0 (NA) 5.6 1.2, 17.8 5.8 (3.0, 8.3) NR HER2 low BC 10/26, 38.5% (20.2, 59.4) 23/26, 88.5% (69.8, 97.6) NR 4.9 0.5, 16.1 13.6 (NA) NR Other HER2 expressing solid tumors 8/22, 36.4% (17.2, 59.3) 18/22, 81.8% (59.7, 94.8) NR 8.1 0.7, 15.0 NR NR *Sbj who received 5.4 or 6.4 mg/kg with 2 ps (N=141), or PD prior to 2nd ps (N=19), excluding 40 sbj too early to evaluate. Two low-HER2 GC sbj are not included in the Table; 1 had a confirmed response.
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
Authors: Yihebali Chi, Zhiwei Fang, Xiaonan Hong, Yang Yao, Ping Sun, Guowen Wang, Feng Du, Yongkun Sun, Qiong Wu, Guofan Qu, Shusen Wang, Jianmin Song, Jianchun Yu, Yongkui Lu, Xia Zhu, Xiaohui Niu, Zhiyong He, Jinwan Wang, Hao Yu, Jianqiang Cai
Journal: Clinical Cancer Research (2018)

Purpose: The prognosis for patients with refractory soft-tissue sarcoma (STS) is dismal. Anlotinib has previously shown antitumor activity on STS in preclinical and phase I studies.Patients and Methods: Patients 18 years and older, progressing after anthracycline-based chemotherapy, naïve from angiogenesis inhibitors, with at least one measurable lesion according to RECIST 1.1, were enrolled. The main subtypes eligible were undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), leiomyosarcoma (LMS), synovial sarcoma (SS), fibrosarcoma (FS), alveolar soft-part sarcoma (ASPS), and clear cell sarcoma (CCS). Participants were treated with anlotinib. The primary endpoint was progression-free rate at 12 weeks (PFR12 weeks).Results: A total of 166 patients were included in the final analysis. Overall, the PFR12 weeks was 68%, and objective response rate was 13% (95% confidence interval, 7.6%-18%). The median progression-free survival (PFS) and overall survival (OS) were 5.6 and 12 months, respectively. The PFR12 weeks, median PFS and OS were: 58%, 4.1 and 11 months for UPS (n = 19); 63%, 5.6 and 13 months for LPS (n = 13); 75%, 11 and 15 months for LMS (n = 26); 75%, 7.7 and 12 months for SS (n = 47); 81%, 5.6 and 12 months for FS (n = 18); 77%, 21 and not reached for ASPS (n = 13); 54%, 11 and 16 months for CCS (n = 7); and 44%, 2.8 and 8.8 months for other sarcoma (n = 23), respectively. The most common clinically significant grade 3 or higher adverse events were hypertension (4.8%), triglyceride elevation (3.6%), and pneumothorax (2.4%). No treatment-related death occurred.Conclusions: Anlotinib showed antitumor activity in several STS entities. The toxicity was manageable. Clin Cancer Res; 24(21); 5233-8. ©2018 AACR.
SAT0319 Description of musculoskeletal symptoms in a cohort of patients with psoriasis
Authors: C. Magee, F. Farkas, N. Ikumi, A. Szentpetery, P. Gallagher, B. Kirby, O. Fitzgerald
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The BIOmarkers of COMorbidities (BIOCOM) in Psoriasis (Pso) study is a longitudinal study which aims to identify clinical, genetic or protein biomarker features associated with the development of co-morbidities, notably Psoriatic Arthritis (PsA) in patients with Pso. Pso usually precedes the development of PsA with an average interval of 10 years. Thus, Pso patients are an ideal group in which to study the early events in the evolution to PsA. <h3>Objectives</h3> Herein we describe the baseline clinical features in this BIOCOM cohort. Based on these features, we categorise patients into groupings which may be helpful during long-term follow-up. <h3>Methods</h3> Patients are being recruited from the dermatology clinics at St. Vincent's University Hospital, Dublin. Inclusion criteria included a diagnosis of Pso with disease duration of less than 10 years and an age of 18 years or older. Patients with another serious active medical illness, a previous diagnosis of inflammatory arthritis or those who were receiving systemic immunosuppressant therapy for Pso were excluded Following recruitment, patients were assessed for musculoskeletal (MSK) signs or symptoms: questionnaire detailing history of any MSK complaints including inflammatory back pain, full physical examination including evidence of tender or swollen joints and entheseal tenderness (using the Leeds Enthesitis Index) and routine blood testing including inflammatory markers. If patients had any MSK findings they underwent routine radiographs, MRI scanning or ultrasound scanning as indicated. Patients were then categorised using all information available as follows: Pso only; Pso+: MSK signs or symptoms but insufficient for diagnosis of PsA; PsA (CASPAR): Diagnosis of PsA meeting CASPAR criteria; Other Rheumatic Disease. <h3>Results</h3> To date 190 patients with Psoriasis have been recruited. Of those, 9 were excluded due to a diagnosis of Pso &gt;10 years previously. One was excluded due to a previous diagnosis of JIA Of the remaining 180 patients: 106 were male (58.9%). Mean age was 41.5±14.8 years. Average duration of Pso: 6.1±2.9 years. On examination: 126 (70%) had psoriatic nail disease (pitting, ridges or onycholysis). 84 patients had no musculoskeletal signs or symptoms. The remaining 96 patients had at least one musculoskeletal finding as outlined in table 1 below. <h3>Conclusions</h3> Analysis of patients recruited to date for the BIOCOM-Pso study shows that at baseline at least one third of patients with Pso had non-specific MSK signs and symptoms. Previous studies suggest these patients may be more likely to subsequently develop PsA. By following this cohort prospectively, we hope to better characterise which features are predictive of the development of PsA in patients with Pso. <h3>Disclosure of Interest</h3> None declared
Hunger and malnutrition in the 21st century
Authors: Patrick Webb, Gunhild Anker Stordalen, Sudhvir Singh, Ramani Wijesinha-Bettoni, Prakash Shetty, Anna Lartey
Journal: BMJ (2018)

Despite record food output globally, hunger is still with us. <b>Patrick Webb and colleagues</b> argue that key policy actions are urgently needed to tackle this scourge and must focus on improving diet quality for all
Клінічні форми лактазної недостатності в дітей
Authors: T.V. Sorokman, N.A. Popelyuk, L.V. Shvygar
Journal: GASTROENTEROLOGY (2018)

Актуальність. Лактазна недостатність (ЛН) — найбільш часта патологія тонкої кишки, для якої характерний розвиток синдрому порушеного травлення і всмоктування, пов’язаного з відсутністю або недостатньою активністю ферменту лактази. Мета дослідження: вивчити особливості перебігу різних клінічних форм ЛН у дітей. Матеріали та методи. Під спостереженням перебували 40 дітей (21 хлопчик та 19 дівчаток) різних вікових категорій з діагнозом «лактазна недостатність». Проводилося дослідження: копрограма, визначення pH, загальний вміст вуглеводів, навантаження лактозою, вміст лактози в сечі. Оцінка вірогідності здійснювалася за допомогою критерію Стьюдента (t). Результати. Виділено чотири клінічні форми ЛН: перша група — ЛН із повною відсутністю ферменту (алактазія, 4 особи), друга — ЛН із частковою недостатністю ферменту (гіполактазія, 10 осіб), третя — ЛН із лактозурією (4 особи), четверта — транзиторна ЛН (22 особи). Клінічна картина проявлялася рідкими (100 %), пінистими (83,3 %), із кислим запахом (83,3 %) випорожненнями. У третини дітей із ЛН спостерігалися зригування, у 75,0 % — абдомінальні коліки. У всіх дітей відмічалися дефіцит маси тіла та дефіцитні анемії. Висновки. Найбільш часто спостерігається транзиторна (вторинна) лактазна недостатність, що перебігає в легкій формі в дітей різних вікових категорій. Алактазія характерна для дітей до 1 року життя, перебігає з вираженими клінічними ознаками на фоні дефіциту маси тіла та анемії. Гіполактазія перебігає з помірно вираженими клінічними симптомами. ЛН із лактозурією характерна для недоношених дітей.
Factors Associated With Recurrence of Barrett’s Esophagus After Radiofrequency Ablation
Authors: Mimi C. Tan, Kavin A. Kanthasamy, Allison G. Yeh, Daniel Kil, Lisa Pompeii, Xiaoying Yu, Hashem B. El-Serag, Aaron P. Thrift
Journal: Clinical Gastroenterology and Hepatology (2018)
AB0026 Tlr9 stimulation of anergic hcv-associated atypical memory b cells triggers rheumatoid factor autoimmunity by the tnf-Α pathway
Authors: C. Comarmond, D. Saadoun
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Hepatitis C virus (HCV) infection contributes to the development of autoimmune disorders, but the mechanisms responsible for HCV-associated autoimmunity are not well understood. <h3>Results</h3> Here we show that TLR9 stimulation of atypical memory (AtM) B cells from patients with HCV-associated cryoglobulinemia vasculitis induce the secretion of IFNγ, TNFα but not IL17A by CD4<sup>+</sup>CD25<sup>-</sup> effector T cells and stimulate their proliferation. Conversely, they reduce the proliferative capacity of CD4<sup>+</sup>CD25<sup>hi</sup>CD127<sup>-/low</sup>FoxP3<sup>+</sup> regulatory T cells. TLR9-stimulated AtM secrete TNFα and IgMs with rheumatoid factor activity. We identify a transcriptional signature specific of TLR9-stimulated AtM, centred on TNFα overexpression. AtM B-cell expansions display intraclonal diversity of mutated IgM with features of antigen-driven maturation. AtM-derived antibodies possess rheumatoid factor activity, with each antibody clone targeting a unique epitope on the human IgG Fc region. AtM antibodies are neither polyreactive nor reactive to ubiquitous autoantigens and importantly, not cross-reactive against HCV antigens including NS3 and E2 proteins. <h3>Conclusions</h3> These data strongly suggest a central role for AtM in defective tolerance of HCV-CV patients through TLR9 reactivation of anergic AtM and production of IgM antibodies with rheumatoid factor activity. <h3>Disclosure of Interest</h3> None declared
SAT0543 Quality of life in behÇet’s syndrome: the role of patient reported outcome
Authors: R. Talarico, A. d’Ascanio, R. Neri, C. Tani, C. Baldini, M. Mosca
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Behçet's syndrome (BS) is a systemic vasculitis, typically characterised by recurrent oro-genital ulcers, ocular inflammation and skin manifestations; articular, vascular, gastro-enteric and neurological involvement may also occur.The complex pattern of BS profile can effect negatively on patients' quality of life. <h3>Objectives</h3> The primary aim of this study was to explore the role of quality of life in BD patients by means of patient reported outcome (PRO); the secondary aim was to study any correlation between disease activity and quality of life. <h3>Methods</h3> The study enrolled 130 patients (71 M, 59 F), all fulfilling the International Study Group (ISG) criteria for BS. Their mean age was 42±8 years, 18–77 while the mean age at disease onset was 11±4 years 5–18 and the mean follow-up of 8±2 years. Disease activity was evaluated by means of the Behçet's Disease Current Activity Form (BDCAF), while Short-form-36 (SF-36) was used to evaluate quality of life. Disease activity was compared with the global SF-36 score and with each dimension, that includes: physical functioning, physical disability, body pain, general health, vitality, social functioning, emotional disability, mental health. The statistical analysis was performed using Student t-test, Mann-Whitney-U test, ANOVA and Pearson correlation <h3>Results</h3> At time of evaluation, according BDCAF, 51 BS patients (39%) had clinically active disease (36 muco-cutaneous involvement, 21 ocular involvement 10 joint involvement, 6 neurological involvement, 4 gastro-enteric). As expected, the overall SF-36 scores were significantly lower in patients with clinically active disease. Moreover, female BS patients had statistically significant lower scores in all SF-36 domains compared with male patients. When each domain of SF-36 was evaluated, we found that physical disability (p=0.004), body pain (p=0.006), general health (p=0.001), and vitality (p=0.001) were significantly lower in patients with disease activity. Notably, vitality (p=0.001), physical disability(p=0.004), social functioning (p=0.001), emotional disability (p=0.003) and mental health (p=0.001) were significantly lower in patients with muco-cutaneous active disease, compared with the other patients with active disease. <h3>Conclusions</h3> The clinicians who take care of any chronic disease would like to correctly know the current status of a patient to manage him properly. In this regard, the combination data of PRO measures and disease activity have been demonstrated to add more information compared to the evaluation of disease activity alone. These consideration suggest that the correct assessment of BS needs a multi-dimensional approach, that fairly includes disease activity, disease damage and quality of life <h3>Disclosure of Interest</h3> None declared